These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24516235)

  • 21. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.
    Bataille S; Pelletier M; Sallée M; Berland Y; McKay N; Duval A; Gentile S; Mouelhi Y; Brunet P; Burtey S
    BMC Nephrol; 2017 Jul; 18(1):251. PubMed ID: 28747155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.
    Castillo N; García-García P; Rivero A; Jiménez-Sosa A; Macía M; Getino MA; Méndez ML; García-Pérez J; Navarro-González JF
    BMC Nephrol; 2012 Jul; 13():60. PubMed ID: 22799577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.
    Ryta A; Chmielewski M; Debska-Slizien A; Jagodzinski P; Sikorska-Wisniewska M; Lichodziejewska-Niemierko M
    Int Urol Nephrol; 2017 May; 49(5):903-908. PubMed ID: 28058668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
    Portolés J; López-Gómez JM; Aljama P
    Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
    Minutolo R; Locatelli F; Gallieni M; Bonofiglio R; Fuiano G; Oldrizzi L; Conte G; De Nicola L; Mangione F; Esposito P; Dal Canton A;
    Nephrol Dial Transplant; 2013 Dec; 28(12):3035-45. PubMed ID: 24145459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life of patients with chronic renal allograft rejection and anemia.
    Rebollo P; Baltar JM; Campistol JM; Ortega T; Ortega F
    J Nephrol; 2004; 17(4):531-6. PubMed ID: 15372415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia, inflammation and health-related quality of life in chronic kidney disease patients.
    Farag YM; Keithi-Reddy SR; Mittal BV; Surana SP; Addabbo F; Goligorsky MS; Singh AK
    Clin Nephrol; 2011 Jun; 75(6):524-33. PubMed ID: 21612756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
    Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
    Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusion burden among patients with chronic kidney disease and anemia.
    Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
    Lines SW; Lindley EJ; Tattersall JE; Wright MJ
    Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life in end stage renal disease: a multicentre comparative study.
    Gayle F; Soyibo AK; Gilbert DT; Manzanares J; Barton EN
    West Indian Med J; 2009 Jun; 58(3):235-42. PubMed ID: 20043531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up.
    Macdougall IC; Tomson CR; Steenkamp M; Ansell D
    Nephrol Dial Transplant; 2010 Mar; 25(3):914-9. PubMed ID: 19934090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and predictors of the sub-target Hb level in children on dialysis.
    van Stralen KJ; Krischock L; Schaefer F; Verrina E; Groothoff JW; Evans J; Heaf J; Ivanov D; Kostic M; Maringhini S; Podracká L; Printza N; Pundziene B; Reusz GS; Vondrak K; Jager KJ; Tizard EJ;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3950-7. PubMed ID: 22740719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia.
    Viganò SM; Filippo SD; Milia VL; Pontoriero G; Locatelli F
    Int J Artif Organs; 2012 May; 35(5):346-51. PubMed ID: 22684617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.